Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event ...
Affinity Technologies shares 3 new case studies in which CyPath Lung detected Stage 1A lung cancer or prevented unnecessary ...
Opportunities in the medical device market lie in mastering regulatory requirements and clinical evidence gathering for CE marking and compliance. Understanding data collection needs, conducting ...
Dr. Alexander Spira explained the difference between a clinical trial and a real-world study in a CURE interview for patients with lung cancer. Real-world studies represent an important step in the ...
MedPage Today on MSN
Case Study: A Strange Initial Diagnosis in a Myeloma Patient
Although there was no evidence of proteinuria, hematuria, or kidney dysfunction at the time of the MGUS diagnosis, the ...
Preclinical in vitro studies demonstrated >80% reduction in protease activity, including complete inhibition of TACE and collagenase — key factors in non-healing chronic wounds revyve® data featured ...
Clinical trials frequently struggle with challenges due to slow enrollment, poor patient retention and operational delays, which can result in rescue studies. Learn how Quest Diagnostics and ...
AI also improves the negotiation process by surfacing fallback clauses and highlighting site-specific preferences. If an institution like Mass General or MSK insists on certain language, the system ...
~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies & ...
"The findings are very exciting,” said Dr. Prachi Singh at Pennington Biomedical. “This supports the growing understanding ...
Opinion
Opinion
Clinical Trials Arena on MSNWhat clinical trial sponsors need to know about anonymisation and pseudonymisation of data
Melissa Hall, legal director in MFMac’s Healthcare & Life Sciences team, reflects on what the UK Information Commissioner Office’s (ICO) new guidance around data could mean for clinical trials.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results